title: Oral direct inhibitors of coagulation.
abstract: For the first time in 50 years new oral anticoagulants of proven efficacy and with acceptable safety profiles are available for patients with atrial fibrillation and venous thromboembolism. Here is a brief overview of the benefits and possible disadvantages of using these drugs.
authors.affiliation: HG Watson Department of Haematology Aberdeen Royal Infirmary Aberdeen, AB25 2ZN UK e-mail henrywatson@nhs.net.
authors.forename: H G
authors.initials: HG
authors.lastname: Watson
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D001562:Benzimidazoles / Q000627:therapeutic use*; D000069604:Dabigatran; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D011728:Pyridones / Q000627:therapeutic use*; D000069552:Rivaroxaban; D013876:Thiophenes / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D009025:Morpholines; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013876:Thiophenes; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran
keywords: Dabigatran; anticoagulation; apixaban; atrial fibrillation; rivaroxaban; venous thromboembolism